sarepta-home2

At Long Last, A Victory!

This brave and beautiful community has demonstrated in various ways, that this one life will be well-spent, focused on changing the landscape for our children. Today was a day we don’t see nearly enough in our community today was a victory! Learn more about what today's news from Sarepta may mean for your child, as well as what we can expect next.
April 21, 2014 | Learn more 

sarepta-home

Sarepta Announces Plans to Submit New Drug Application to FDA for Eteplirsen for the Treatment of Duchenne by Year End 2014

Sarepta Therapeutics today announced it plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) by the end of 2014 for the approval of eteplirsen for the treatment of Duchenne. Eteplirsen is Sarepta’s lead exon-skipping drug candidate in development for the treatment of patients with Duchenne who have a genotype amenable to skipping of exon 51.
April 21, 2014 | Learn more 

News Update - eNews

End Duchenne eNews: Transforming Duchenne Care

Catch up on the latest research and community updates in this month's End Duchenne eNews.
April 15, 2014 | Learn more 

adv-imp

A New Care Guide to Give to Your Provider – Imperatives for Duchenne Care

Health care providers care for many people, with many diagnoses – far too many for any one provider to be an expert in them all. Make sure that you are receiving the best possible care by giving your provider this NEW "cheat sheet" guide to comprehensive ‪‎Duchenne care.
April 14, 2014 | Learn more 

adv-web2

Prosensa Update on Drisapersen (webinar)

Prosensa presented a status update on Drisapersen and its follow-on compounds in a patient focused webinar hosted by United Parent Projects Muscular Dystrophy (UPPMD) on Tuesday, March 25th at 1 PM ET.
March 31, 2014 | Learn more 

news-update-exploratory-grant

PPMD Awards $100,000 in Exploratory Grants

PPMD is thrilled to award two exploratory grants as part of our ongoing grant program. Peter Arthur of the University of Western Australia was awarded $50,000 to finish testing a molecule called procysteine in animal models in preparation for a human clinical trial. PPMD has also awarded ReveraGen BioPharma an award of $50,000 to determine if small snippets of RNA called "microRNAs" can affect the efficiency of exon-skipping.
March 25, 2014 | Learn more 

News Update - Care

NEW Certified Duchenne Care Center Program

PPMD is proud to award Nationwide Children’s Hospital as our first Certified Duchenne Care Center. Every person with Duchenne deserves the best care and treatment possible, and has the right to know what clinics meet optimal standards. This program will do just that.
March 20, 2014 | Learn more 

homepage-actionalert2

Action Alert: Ensuring Federal Agencies Working on Duchenne Receive Proper Funding

While the MD-CARE Act remains a top priority, we need to also make sure that federal agencies receive adequate funding and direction for the programs that are so critical to our community. One tool we use to ensure that funding and direction is our Congressional funding letter. The investment to date is over $250 million on Duchenne let's keep adding to that number. It takes less than a minute to send your message to Congress.
March 14, 2014 | Take Action

2013 Connect Conference

Registration for PPMD's 20th Annual Connect Conference is now open

This year marks PPMD's 20th Annual Connect Conference in Chicago, June 26-29, 2014. Join families, physicians, researchers, industry leaders, and experts of all kinds as we gather to speak face-to-face about Duchenne.
March 12, 2014 | Learn more

 
Connect with PPMD
Facebook YouTube Twitter

 

Fund Research

Quick Links
PPMD Sites
Pat's Blog

Pat's BlogAt Long Last, A Victory!

Learn more about what Sarepta's announcmeet regarding eteplirsen may mean for your child, as well as what we can expect next.

April 21, 2014 | Read more


Shop Amazon, End Duchenne

How We Help